Future of Weight Loss
Exciting advancements in weight loss medications are on the horizon, particularly with terzepatide, which shows promising results in weight reduction and fewer side effects compared to existing options. A new triple agonist currently in trials could revolutionize treatment by combining GLP-1, GIP, and glucagon, potentially leading to over 25% weight loss, comparable to bariatric surgery outcomes. This innovative approach not only enhances weight loss but also mitigates nausea, paving the way for more effective obesity management.In this clip
From this podcast
Huberman Lab
Dr. Zachary Knight: The Science of Hunger & Medications to Combat Obesity
Related Questions
How does terzepatide compare to other GLP-1 agonists in the episodes Dr. Zachary Knight: The Science of Hunger & Medications to Combat Obesity and Future of Weight Loss?
What is the weight loss difference between Ozempic (semaglutide) and Mounjaro (tirzepatide) in the episodes Dr. Zachary Knight: The Science of Hunger & Medications to Combat Obesity and Future of Weight Loss?
How effective are GLP-1 agonists like Ozempic for weight loss?